Eledon Pharmaceuticals(US:ELDN)2025-05-14 20:05Financial Performance - Eledon Pharmaceuticals reported cash, cash equivalents, and short-term investments of $124.9 million as of March 31, 2025, down from $140.2 million as of December 31, 2024[6]. - The net loss for Q1 2025 was $6.5 million, or $0.08 per share, significantly improved from a net loss of $23.6 million, or $0.79 per share, in Q1 2024[9]. - Total operating expenses for Q1 2025 were $18.0 million, compared to $10.9 million in Q1 2024, indicating a 65% increase[16]. - The company expects its current cash and investments to fund operations through the end of 2026[6]. Research and Development - Research and development expenses for Q1 2025 were $13.5 million, a 82% increase from $7.4 million in Q1 2024[7]. - General and administrative expenses for Q1 2025 were $4.4 million, compared to $3.5 million in Q1 2024, reflecting a 26% increase[8]. - Eledon is on track to report topline results from the Phase 2 BESTOW trial in kidney transplantation in Q4 2025[2]. - The company plans to report updated interim clinical data from the ongoing Phase 1b open-label trial in August 2025[5]. - Eledon anticipates reporting updated interim clinical data from a trial with UChicago Medicine in late 2025[5]. - Tegoprubart was used in the second transplant of a genetically modified pig kidney into a human, marking a significant milestone in the company's research[3].